Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Low-Density Granulocytes Activate T Cells in SLE

Lara C. Pullen, PhD  |  June 17, 2019

Over the past decade, the understanding of neutrophil biology has grown tremendously. Research has revealed that low-density neutrophil populations, such as low-density granulocytes, may be proinflammatory, whereas polymorphonuclear myeloid-derived suppressor cells are immunosuppressive. Patients with systemic lupus erythematosus (SLE) have elevated levels of both low-density granulocytes and polymorphonuclear myeloid-derived suppress cells. Moreover, in SLE patients, low-density granulocytes are highly susceptible to the formation of neutrophil extracellular traps (NETs), which can lead to immune dysregulation, the activation of plasmacytoid dendritic cells and the myeloid type I interferon axis, and the induction of an interferon gene signature.

The connection between low-density granulocytes and the type I interferon pathway may be particularly important for SLE patients because this pathway plays a role in SLE pathogenesis and disease exacerbation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Recent research indicates low-density granulocytes from SLE patients exert proinflammatory effects on T cells. Saifur Rahman of the Allan Institute of Immunology, Seattle, and colleagues note the SLE low-density granulocytes don’t exhibit myeloid-derived suppressor cell function. The results, published online April 30 in the Annals of Rheumatic Diseases, are consistent with the idea that low-density granulocytes represent a distinct proinflammatory subset with pathogenic potential in SLE patients. This may be, at least in part, because the granulocytes can activate type 1 helper responses.1

In the study, the investigators compared low-density granulocytes from SLE patients with low-density granulocytes from age-matched healthy controls. They confirmed low-density granulocyte prevalence was elevated in SLE relative to healthy controls. They found low-density granulocytes in SLE patients displayed an activated phenotype and were associated with the interferon 21-gene signature and disease activity. Although both the interferon gene signature and the neutrophil-to-lymphocyte ratio are strong indicators of inflammation, the researchers found the low-density granulocyte-to-lymphocyte ratio associated better with the SLE disease activity index than did the neutrophil-to-lymphocyte ratio.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After the investigators confirmed the high prevalence of low-density granulocytes across the SLE disease spectrum, they evaluated the immunophenotype of the cells. Although they found few differences between the low-density granulocytes of SLE patients and healthy controls, they found many differences between SLE low-density granulocytes and SLE normal-density granulocytes. Specifically, low-density granulocytes had significantly reduced nuclear area, cell area and cell diameter and a lower nuclear-to-cytoplasm ratio relative to normal-density granulocytes.

All the low-density granulocytes exhibited significantly elevated surface expression of multiple activation markers, including LOX-1, CD63 and the lectin-like oxidized low-density lipoprotein receptor 1. LOX-1 and the lectin-like oxidized low-density lipoprotein receptor 1 markers were previously reported to be primarily associated with polymorphonuclear myeloid-derived suppress cells. CD63 is recognized as a granulocyte activation marker.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:low-density granulocytesLupusSLEsystemic lupus erythematosus (SLE)

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    July 18, 2019

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

    Multiple Interferons, Including IFNB1, May Play a Role in SLE

    August 14, 2019

    A recent gene expression analysis found an enriched downstream interferon signature, with predominantly IFNB1 signatures in systemic lupus erythematosus (SLE) patients. The study also found lower expression of all downstream interferon signatures in the kidneys of lupus nephritis patients…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences